GlaxoSmithKline Pharmaceuticals Limited · NSE:GLAXO
GlaxoSmithKline Pharmaceuticals — FY2013 Earnings Presentation
8 slides from GlaxoSmithKline Pharmaceuticals's earnings presentation, Feb 25, 2014
Slide 1: Financial Results 2013
Financial Results 2013 25th February 2014 Financial Results Q4 2013 1
Slide 2: Financial Summary - 2013
Financial Summary - 2013 INR Cr YTD 2013 YTD 2012 Net Sales 2,520.2 (3.1) 2,599.9 Pharma 2,325.4 (4.3) 2,429.3 Ostocalcium (CH) 43.8 (14.2) 51.0 Iodex (CH) 141.5 41.5 100.0 Exports 9.5 (51.7) 19.6 Other Operating Income 26.0 26.5 % to Sales 1% 1% Pharma 15.1 16.0 Other Businesses 10.9 10.5 Total Mat
Slide 3: Financial Summary - 2013 (Employee Benefits, Opex)
Financial Summary - 2013 INR Cr YTD 2013 YTD 2012 Employee Benefits 362.1 (22.5) 295.5 % to Sales 14% 11% Pharma 341.0 276.2 Other Businesses 21.0 19.3 Opex 549.2 (18.6) 463.2 Pharma 434.3 (11.3) 390.3 Other Businesses 106.7 (39.5) 76.5 Excise duty on Inventory changes 8.2 (3.6) Depreciation 19.9 17
Slide 4: Financial Summary - 2013 (Profit)
Financial Summary - 2013 INR Cr YTD 2013 YTD 2012 Profit from Operations 502.2 (37.0) 797.4 % to Sales 20% 31% Pharma 446.7 (38.2) 723.3 Other Businesses 55.5 (25.1) 74.1 Investment Income / Other Income 201.0 197.4 PBT before Exceptionals 703.2 (29.3) 994.8 % to Sales 28% 38% Exceptional Items (Gro
Slide 5: SBU wise Sales Performance
SBU wise Sales Performance INR Cr SBU VERTICALS FY'13 Gr% Mass Markets 797 -12% Mass Specialty 577 -12% Speciality 590 9% Derma 455 7% Others 135 14% Vaccines 362 12% Total Rx 2,325 -4.3% Financial Results FY 2013 5
Slide 6: Exceptional Items
Exceptional Items INR Cr 2013 Thane Operating Costs (Net) 2.19 Write back of provisions for formulations (5.63) Profit on sale of property (21.18) Actuarial gain/(loss) on employee benefits (1.53) (26.15) Financial Results Q4 2013 6
Slide 7: Cash Flow
Cash Flow 2013 2012 INR Cr Profit before taxation and exceptional items 703 995 Depreciation and other non-operating activities (180) (179) Operating profit before working capital changes 523 816 Adjustments for : Inventories (60) 47 Sundry Debtors 20 (28) Trade payables and other liabilities net of
Slide 8: Financial Performance
Financial Performance EPS and Book Value per share (INR) Return on Avg. Net Worth 66.6 68.2 ` ` 60.5 59.3 50.8 237 238 228 227 31.0 30.6 29.4 24.9 208 22.4 Book value EPS 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 Dividend Payout (INR) 99% 70% 103% 85% 58% 45 50 50 40 30 2009 2010 2011 2012 2
GlaxoSmithKline Pharmaceuticals — FY2013 Earnings Presentation on 6ix